Investors are better served ignoring the market's monthly whims and whispers and focusing instead on discovering stocks with long term tailwinds.
In biopharma, that means keeping an eye on drug spending trends, which measure both drug prices and total prescription volume, and patient population forecasts, which provide insight into whether the market for drug treatment is likely to grow or shrink.
After reviewing Express Scripts' annual drug spending trend report, one disease category stands out for both its significant current spending and its potential for future growth. That category is expected to post double digit growth in spending in each of the next three years, providing significant revenue opportunity for Sanofi (NYSE:SNY) and Merck (NYSE:MRK)
In the following slideshow you'll learn what this one big drug spending trend is and how rapid growth in treating one of the most prevalent diseases in America may drive Sanofi and Merck's shares higher.
6 stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned.
The Motley Fool recommends Express Scripts. The Motley Fool owns shares of Express Scripts. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.